TABLET Trial Summary: Dhillon-Smith R et al. randomized 952 women with positive testing for thyroid peroxidase antibodies and normal thyroid function and a history of miscarriage or infertility to either levothyroxine 50 μg once daily (n=476) or placebo (n=476). The primary objective was to assess if levothyroxine treatment would increase live-birth rates among euthyroid women who had thyroid peroxidase antibodies and a history of miscarriage or infertility. No difference was noted among the primary outcome of live birth at >34 weeks gestation (RR 0.97; 95% CI, 0.83 to 1.14, P=0.74). There were no difference in adverse events. The authors of the TABLET trial concluded that the use of levothyroxine in euthyroid women with thyroid peroxidase antibodies did not result in a higher rate of live births than placebo.